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Abstract
Background: The purpose of this study was to compare plasma levels of antioxidants and oxidative stress biomarkers in head
and neck squamous cell carcinoma (HNSCC) patients with healthy controls. Furthermore, the effect of radiotherapy on these
biomarkers and their association with survival in HNSCC patients were investigated.
Methods: Seventy-eight HNSCC patients and 100 healthy controls were included in this study. Follow-up samples at the end
of radiotherapy were obtained in 60 patients. Fifteen antioxidant biomarkers (6 carotenoids, 4 tocopherols, ascorbic acid, total
antioxidant capacity, glutathione redox potential, total glutathione and total cysteine) and four oxidative stress biomarkers (total
hydroperoxides, γ-glutamyl transpeptidase, 8-isoprostagladin F2α and ratio of oxidized/total ascorbic acid) were measured in
plasma samples. Analysis of Covariance was used to compare biomarkers between patients and healthy controls. Kaplan-Meier
plots and Cox' proportional hazards models were used to study survival among patients.
Results: Dietary antioxidants (carotenoids, tocopherols and ascorbic acid), ferric reducing antioxidant power (FRAP) and
modified FRAP were lower in HNSCC patients compared to controls and dietary antioxidants decreased during radiotherapy.
Total hydroperoxides (d-ROMs), a marker for oxidative stress, were higher in HNSCC patients compared to controls and
increased during radiotherapy. Among the biomarkers analyzed, high levels of plasma carotenoids before radiotherapy are
associated with a prolonged progression-free survival (hazard rate ratio: 0.42, 95% CI: 0.20-0.91, p = 0.03). Additionally, high
relative increase in plasma levels of d-ROMs (hazard rate ratio: 0.31, 95% CI: 0.13-0.76, p = 0.01) and high relative decrease in
FRAP (hazard rate ratio: 0.42, 95% CI: 0.17-0.998, p = 0.05) during radiotherapy are also positively associated with survival.
Conclusions: Biomarkers of antioxidants and oxidative stress are unfavourable in HNSCC patients compared to healthy
controls, and radiotherapy affects many of these biomarkers. Increasing levels of antioxidant biomarkers before radiotherapy
and increasing oxidative stress during radiotherapy may improve survival indicating that different factors/mechanisms may be
important for survival before and during radiotherapy in HNSCC patients. Thus, the therapeutic potential of optimizing
antioxidant status and oxidative stress should be explored further in these patients.
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Background
Mammalian cells are constantly exposed to oxidative
stress and rely on a comprehensive array of antioxidant
defence comprising of both enzymatic and non-enzy-
matic molecules [1]. Among non-enzymatic molecules,
both endogenous- (e.g. thiol-containing compounds like
glutathione) and dietary- (e.g., phytochemicals like caro-
tenoids, vitamin E, vitamin C and polyphenols) low
molecular weight antioxidants have shown to effectively
neutralize reactive oxygen species (ROS) and reactive
nitrogen species (RNS). Dietary antioxidants that work
complementary to endogenous antioxidants in removing
free radicals directly [2-4], may also up regulate different
genes involved in the endogenous antioxidant defence
[5].
It is hypothesized that oxidative stress is involved in the
pathogenesis of different types of cancer [6-8]. Head and
neck squamous cell carcinoma (HNSCC) has a strong link
to oxidative stress since tobacco and alcohol are clearly
defined as etiologic factors for these malignancies [9,10].
Furthermore, several studies have shown that the risk of
developing HNSCC is linked to low intake of fruits and
vegetables, certain genotypes of the enzymes glutathione
S-transferases (GSTs) and human papillomavirus (HPV)
infection [10-13]. All of these factors are known to
increase ROS and RNS production, and to induce cellular
oxidative damage.
Radiotherapy is a cornerstone in the treatment of HNSCC.
Ionic irradiation exposes all cells in the involved field to
high levels of oxidative stress resulting in formation of
ROS, increasing DNA damage and ultimately leading to
cell death [14]. Another mechanism of action of radio-
therapy is to alter cellular homeostasis, modifying signal
transduction pathways and disposition to apoptosis [14].
The nutritional status of HNSCC patients often reflects
pre-diagnostic life style factors like smoking, drinking and
low intake of fruits and vegetables, as well as changes in
eating habits due to the tumour and adverse effects of
radiotherapy. Although there have been advances in treat-
ment, five-year survival rates in these patients has
remained around 50-60% [10]. Some reports have shown
that plasma levels of β-carotene, lycopene and vitamin E
are lower in HNSCC [15-17] and oral leukoplakia patients
[18,19] as compared to healthy controls. The effects of
radiotherapy on antioxidants and oxidative stress biomar-
kers, and their association to survival are known to a
much lesser extent. In a pilot study including 29 HNSCC
patients, we observed that high levels of post-radiother-
apy plasma total glutathione (GSH) [20] and carotenoids
[21] were associated with increased survival in HNSCC
patients.
We suggest that improved knowledge on the antioxidant
and oxidative stress status, the impact of radiotherapy on
this status, and its association with outcome could be use-
ful for improving survival in these patients. Thus, in this
study we have assessed an extensive profile of plasma low
molecular weight antioxidants (endogenous and dietary)
and oxidative stress markers before radiotherapy and
monitored their respective response to radiotherapy in
HNSCC patients. Furthermore, we have investigated how
these parameters are related with survival.
Methods
Selection of patients and controls
Eighty-seven patients with histologically verified HNSCC
were recruited from Division of Cancer Medicine and
Radiotherapy, Norwegian Radium Hospital, Rikshospi-
talet University Hospital in the period from May 2003 to
May 2006. Seventy-eight patients were found eligible (two
patients did not receive complete radiotherapy and 7
patients had previous history of cancer) in this prospec-
tive study. Follow-up samples at the end of radiotherapy
were obtained from 60 patients. Of these 60 patients,
twenty-four received assisted nutrition during radiother-
apy.
The patients received either post-operative radiotherapy
or radiotherapy alone for a period of 5-7 weeks. All
patients received external photon beam radiotherapy. The
standard radiation technique used at the time of enrol-
ment was computer tomography based conformal radio-
therapy. Of the 78 patients included in the study, 50
patients received 70 Gy, 6 patients received 66 Gy, 1
patient received 64 Gy, 16 patients received 60 Gy (one
died after 60 Gy) , 4 patients received 50 Gy and one
patient died after 44 Gy. The patients receiving 70 Gy
postoperatively had performed debulking surgery of the
primary tumour and received 70 Gy to macroscopic
lymph nodes in the neck and/or the primary tumour area.
One patient received a split course accelerated hyperfrac-
tionated regimen with 1.5 Gy × 2 per day in 20 days (5
days per week). 76 patients received 2 Gy fractions 5 days
weekly, but two of three patients with nasopharyngeal car-
cinomas received concomitant chemotherapy according
to the Dahanca 14 protocol. The regimen used was cispl-
atin 40 mg/m2 weekly and 6 fractions per week. One
patient with nasopharyngeal carcinoma did not receive
concomitant chemotherapy because of co-morbidity and
high age. At the time of enrolment, concomitant chemo-
therapy was not the standard care at The Norwegian
Radium Hospital.
Fasting plasma from 100 control individuals, matched
with respect to age range, gender and smoking status with
HNSCC patients were selected. These controls were
selected from a cohort of 356 participants in a validationBMC Cancer 2009, 9:458 http://www.biomedcentral.com/1471-2407/9/458
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study conducted at the University of Oslo (Anette Karlsen,
personal communication). Participants were recruited
after response to an invitation letter that was sent to a ran-
dom selection of citizens in the Norwegian capital city
and surrounding area. The aims of the validation study
were first to validate a new food frequency questionnaire,
and secondly to investigate normal ranges of nutrition-
related biomarkers measured in blood samples. The distri-
bution of participants intended to reflect the general pop-
ulation and few exclusion criteria were defined. However,
participants with self-reported diseases were excluded
before the control group for this study was selected.
The basic characteristics of controls and patients are sum-
marised in Table 1.
The study was approved by The Regional Committee for
Medical Research Ethics. All the patients and controls gave
their written informed consent.
Sample preparation
Blood samples taken before initiation of radiotherapy and
in the last week of radiotherapy were collected in Stabilyte
tubes and Vacutainer cell preparation tubes (CPT) con-
taining sodium heparin as anticoagulant. Stabilyte tubes
were centrifuged at 2800 g, 4°C for 10 minutes. The
plasma obtained was prepared for reduced, oxidized and
total GSH analysis as described in Sakhi et al. [22]. The
CPT was centrifuged at 1750 g, 20°C for 20 minutes. For
ascorbic acid analysis, plasma obtained was treated as
described in Karlsen et al. [23]. For carotenoids, tocophe-
rols, GGT, ferric reducing antioxidant power (FRAP), 8-
isoprostagladin F2α (8-iso PGF2α) and total hydroperox-
ides (d-ROMs), plasma was portioned in 1 ml and snap
frozen in liquid nitrogen and kept at -80°C until analysis.
Blood samples from controls were taken in EDTA (for car-
otenoids and tocopherols) and sodium heparin tubes (for
FRAP, d-ROMs and ascorbic acid).
Analysis
The plasma levels of reduced and oxidized GSH were ana-
lysed as described by Sakhi et al. [24]. Total GSH and
ascorbic acid (reduced and oxidized) were analysed as
described by Bøhn et al. [20] and Karlsen et al. [23],
respectively. Carotenoids and tocopherols were analysed
as described in online supporting material by Karlsen et
al. [25]. Two different modes of total antioxidant capacity
were measured: FRAP and modified FRAP (FRAP without
uric acid and proteins). The reason for measuring these
two modes is that the role of uric acid, contributing 60%
to FRAP measurements, as an endogenous antioxidant is
inconclusive [26]. Thus, by measuring modified FRAP the
effects on other plasma total antioxidants can be more
clearly elucidated. FRAP was measured in untreated
plasma by method described earlier [26]. For preparation
of plasma extracts for modified FRAP, 10 μL uricase (0.1
units/10 μL) in Triz buffer (pH 8.5, 400 mmol/L) were
added to 60 μL plasma. After incubation for 5 min at
room temperature, 120 μL ethanol were added to precip-
itate proteins. Samples were placed at 4°C for 5 min
before centrifugation at 13000 g at 4°C for 5 min. The uric
acid- and protein free- supernatant were used for modified
FRAP analysis.
Table 1: Basic characteristics of patients and healthy controls
Parameters Patients Controls
Age (years)a, b 63 (34-85) 51 (34-80)
BMIa 24.8 (15.8-40.1) 25.8 (19.3-39.6)
Gender Men 69 90
Women 9 10
Tumour localization Larynx 17 -
Hypopharynx 9 -
Oral cavity 21 -
Oropharynx 28 -
Nasopharynx 3 -
Stage 1 6 -
22 0 -
31 7 -
43 5 -
Treatment Surgery+radiotherapy 30 -
Radiotherapy 48 -
Smoking status Never smoker 28 34
Former smoker 22 30
Current smoker 28 36
amedian (range)
bp < 0.001BMC Cancer 2009, 9:458 http://www.biomedcentral.com/1471-2407/9/458
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Total hydroperoxides (d-ROMs) were measured in plasma
by a d-ROM kit as described by the manufacture (Diacron
International, Grosseto, Italy). Plasma γ-glutamyl
transpeptidase (GGT) was analysed using Vitros GGT
slides with a Vitros 950 Chemistry system at the Depart-
ment of Clinical Chemistry, Norwegian Radium Hospital,
Oslo University Hospital. 8-iso-PGF2α was analyzed by
HPLC using MS-MS detector [27]. One ml plasma was
hydrolyzed, acidified and concentrated using a C-18 solid
phase extraction column. The eluate was dried and the res-
idue was dissolved in 150 μL solution (water:methanol,
50:50, v/v). An aliquot of 50 μL sample was injected and
separation was performed on two columns (SUPEL-
COSIL™ ABZ+Plus, 3 μm particle) connected in series. The
mobile phases were (A) acetonitrile/formic acid (100:0.1,
v/v) and (B) water/formic acid (100:0.1, v/v) at a flow rate
of 0.35 mL/min. A gradient elution was used by increasing
mobile phase A from 35% to 55% for 18 min, held for 2
min, and back to 35% mobile phase A in 2 min. MS-MS
was operated in ESI negative mode. The precursor-to-
product ion transitions in multiple reaction monitoring
mode m/z 353.1-193.1 (for 8-iso PGF2α) and m/z 357.1-
197.1 (for internal standard: 8-iso PGF2α-d4) were used
for quantitation.
The redox potential of GSH in plasma was calculated
using Nernst equation as described in Buettner et al. [28].
Statistical analysis
The statistical program package SPSS (Statistical Package
for Social Sciences, version 14.0) was employed. The
biomarkers in pre-radiotherapy patients and controls
were compared by independent samples t-tests. The
groups were further compared, adjusted for age and body
mass index (BMI) quartiles by Analysis of Covariance
(ANCOVA). Paired t- tests were used to compare mean
values before and after radiation therapy. Mean values are
presented, and statistical significance was considered if p-
value < 0.05.
We have used Cox' proportional hazards model to com-
pare the survival distributions of groups with high and
low levels of plasma biomarkers (cut off set to median
value), and to obtain estimated hazard rate ratios.
To obtain adjusted hazard rate ratios, we tested the effect
of a number of possible confounding factors: age, gender,
smoking, treatment, stage, tumour localization and BMI.
The confounding factors that changed the hazard rate
ratios most were included in the final model. The number
of confounding factors that could be included in the
model depends on the sample size and we evaluated to
have maximum 3 confounding factors in our study. Sur-
vival is shown by Kaplan-Meier plots, comparing patients
with levels of biomarkers above and below the median.
For the correlation analyses, Pearson and Spearman's rho
correlation coefficient were calculated.
For clinical outcome, progression-free and overall surviv-
als have been used. Progression-free survival was calcu-
lated from start of radiotherapy until the date of first
distant relapse, local recurrence, regrowth, regional lymph
node metastasis, death from any cause or the last follow-
up examination. Overall survival was calculated from the
start of radiotherapy until death of any cause or last fol-
low-up examination. Loco-regional control was calcu-
lated from start of radiotherapy until the date of local
recurrence, regrowth, regional lymph node metastasis or
the last follow-up examination.
All tests were done two-tailed and p-values < 0.05 consid-
ered statistically significant.
Due to different practical limitations, appropriate sample
collection was not possible for every analysis in all
patients and controls. Thus, the number of samples for
pre-radiotherapy analysis for ascorbic acid, FRAP, modi-
fied FRAP, total GSH, total cysteine, GSH redox potential,
d-ROMs, 8-iso PGF2α and ratio oxidized/total ascorbic
acid (DHAA/TAA) were 73, 76, 76, 77, 77, 67, 76, 77 and
73 respectively. The number of samples for assessing the
changes during radiotherapy for carotenoids, tocopherols,
ascorbic acid, FRAP, modified FRAP, total GSH, total
cysteine, GSH redox potential, d-ROMs, GGT, 8-iso PGF2α
and ratio DHAA/TAA were 59, 59, 51, 57, 57, 57, 57, 50,
57, 59, 57 and 51, respectively. The numbers of control
samples for analysis of tocopherols, FRAP, d-ROMs, total
GSH and total cysteine were 97, 92, 99, 99 and 99, respec-
tively. The remaining biomarkers had data for all patient
and control samples.
Results
Plasma levels of antioxidants and oxidative stress 
biomarkers
HNSCC patients and controls
Mean plasma levels of antioxidants and oxidative stress
biomarkers in healthy controls and HNSCC patients
(both pre- and post- radiotherapy) are shown in Table 2
and 3. Pre-radiotherapy plasma levels of these biomarkers
in HNSCC patients were compared to healthy controls.
All carotenoids (lutein, zeaxanthin, β-cryptoxanthin, α-
carotene, β-carotene, lycopene and total), α-tocopherol,
ascorbic acid, FRAP, modified FRAP and total cysteine
were significantly lower in HNSCC patients as compared
to healthy controls. Total tocopherols also showed a trend
and were lower in patients as compared to healthy con-
trols (p = 0.07). For total carotenoids, total tocopherols,
ascorbic acid, FRAP, modified FRAP and total cysteine the
mean levels were 53%, 92% , 68%, 94%, 50% and 96% of
the controls, respectively. Among oxidative stress parame-BMC Cancer 2009, 9:458 http://www.biomedcentral.com/1471-2407/9/458
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ters, d-ROMs were significantly higher (142%) in patients
as compared to controls. Significant correlations were
observed between stage of disease and pre-radiotherapy d-
ROMs (r = 0.44, p < 0.001), and stage of disease and pre-
radiotherapy total carotenoids (r = -0.31, p = 0.006) indi-
cating that the patients with higher stage have high oxida-
tive stress.
Changes during radiotherapy
Following radiotherapy, we observed a significant decline
in plasma levels of dietary antioxidants including all caro-
tenoids (except β-carotene), tocopherols and ascorbic
acid, (Table 2). The mean decline for total carotenoids,
total tocopherols and ascorbic acid were 33%, 15% and
27%, respectively. Twenty-four patients received assisted
enteral nutrition fortified with β-carotene (130 μg/ml)
during radiotherapy. A sub-group analysis excluding
patients that received enteral nutrition also showed a
Table 2: Antioxidants in healthy controls and patients, both pre- and post radiotherapy
Antioxidantsa Controls Patients
Pre-radiotherapyb Post-radiotherapyc
Carotenoids
(nmol/L)
Lutein 142.5 95.6d 51.0d
Zeaxanthin 35.6 22.4d 12.2d
β-cryptoxanthin 131.3 60.3d 27.5d
α-carotene 107.6 61.3d 56.7e
β-carotene 374.7 241.0d 229.5
Lycopene 533.3 243.9d 124.6d
Total carotenoids 1325.1 703.1d 474.5d
Tocopherols
(μmol/L)
δ-tocopherol 0.030 0.080d 0.042e
β-tocopherol 0.419 0.466 0.362d
γ-tocopherol 1.70 1.72 1.06d
α-tocopherol 28.3 25.7e 22.5d
Total tocopherols 30.5 28.0 23.9d
Vitamin C
(μmol/L)
Ascorbic acid 46.8 31.9d 23.3d
Total antioxidant capacity
(μmol/L)
FRAP 1055 988e 979
Modified FRAP 336 170d 166
Total GSH
(μmol/L)
5.94 5.87 5.63
Total cysteine
(μmol/L)
247.1 236.6e 235.3
GSH redox potential
(mV)
n.a. -148 -147
aMean values
bPre-radiotherapy levels are compared with healthy controls after adjusting for age and BMI
cPre- and post- radiotherapy levels are compared
dp < 0.001, ep < 0.05
n.a. = not available
Table 3: Oxidative stress biomarkers in healthy controls and patients, both pre- and post radiotherapy
Oxidative stress biomarkersa Controls Patients
Pre-radiotherapyb Post-radiotherapyc
d-ROMS (CarrU) 155.9 219.6d 249.8d
GGT (U/L) n.a. 38.9 59.4e
8-iso PGF2α
(pg/mL)
n.a. 28.1 30.9e
DHAA/TAA 0.085 0.089 0.116
aMean values
bPre-radiotherapy levels are compared with healthy controls after adjusting for age and BMI
cPre- and post- radiotherapy levels are compared
dp < 0.001, ep < 0.05
n.a. = not availableBMC Cancer 2009, 9:458 http://www.biomedcentral.com/1471-2407/9/458
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decline for β-carotene (29%, p = 0.06). FRAP, modified
FRAP and endogenous antioxidants (GSH redox poten-
tial, total GSH and cysteine) did not change significantly
during treatment. The oxidative stress markers, d-ROMs,
8-iso PGF2α and GGT increased 14%, 10% and 53%,
respectively during radiotherapy (Table 3).
Clinical outcome
With a median follow-up time for survivors of 28 months
(range 11-48 months), twenty-five patients are dead.
Twenty-three patients died of HNSCC, one patient died of
lung cancer and one patient died of unknown cause.
Thirty-five patients have experienced progression: ten
relapsed patients are alive, eighteen relapsed patients are
dead, and seven patients are dead without previous
relapse or regrowth of tumour. The projected three-year
progression-free and overall survivals were 55% and 68%,
respectively. Table 4 shows mean survival time estimates
in months in all patients, only radiotherapy patients and
post-operative radiotherapy patients for progression-free
survival, overall survival and loco-regional control.
Pre-radiotherapy levels
Above median values of several plasma carotenoids were
significantly associated with improved progression-free
survival. In univariate regression analysis of progression-
free survival, high pre-radiotherapy plasma levels (above
median) of total carotenoids and the single carotenoids
(lutein, zeaxanthin, β-cryptoxanthin and β-carotene) were
significantly associated with prolonged progression-free
survival (Table 5). Plasma α-carotene did also show a
close to significant association with prolonged progres-
sion-free survival (p = 0.06). In multivariate analyses
adjusting for stage, treatment and smoking, these caroten-
oids remained significantly associated to survival (Table
5). The hazard rate ratio, representing the relative risk, was
0.5 for most of the carotenoids after adjusting for con-
founding factors showing that the patients with plasma
carotenoid levels above median have 50% less risk of pro-
gression as compared to patients with plasma carotenoid
levels below the median. Figure 1A presents Kaplan-Meier
plot showing association of total carotenoids with pro-
gression-free survival. Similar results were observed for
overall survival as shown in Table 5.
No association with survival was observed for any other
antioxidant- or oxidative stress biomarkers.
Changes during radiotherapy
Patients with a high relative decrease in the plasma levels
of total antioxidant biomarker FRAP during radiotherapy
have a prolonged progression-free survival as shown in
figure 1B, that remained significant after adjusting for
confounding factors (p = 0.05) (Table 6). No significant
associations between progression-free survival and rela-
tive decrease in plasma levels of any other dietary or
endogenous antioxidants during radiotherapy were
observed.
Patients with a high relative increase (above median) in
the plasma levels of oxidative stress biomarker d-ROMs
have a prolonged progression-free survival (Figure 1C).
The association remained significant after adjusting for
confounding factors (Table 6). The hazard rate ratio was
as low as 0.3 showing that the patients with above median
increase in d-ROMs during treatment period have 70%
less risk of progression as compared to patients with
under median increase in d-ROMs. Similar results were
observed for overall survival as shown in Table 6. Among
other oxidative stress biomarkers, a high relative increases
in plasma levels of 8-iso PGF2α also showed a trend with
prolonged progression-free survival (hazard rate ratio =
0.48, p = 0.08). After adjusting for confounding factors,
the results were similar showing that there is a trend for
50% less risk of progression for patients with above
median increase in plasma levels of 8-iso PGF2α during
radiotherapy (Table 6).
In order to investigate a combined effect of high levels of
total carotenoids and high increase in d-ROMs compared
to low levels of both these factors (above median levels
compared to below median levels), we utilized a two-fac-
tor Cox model. The interaction term turned out non-sig-
nificant and was removed from the model. The risk of
progression (hazard rate ratio: 0.21, 95% CI: 0.07-0.61)
and overall death (hazard rate ratio: 0.13, 95% CI: 0.03-
0.52), respectively, were 80% and 87% less for the
patients with high level of total carotenoids and high
increase in d-ROMs as compared to low levels of both
these factors.
Table 4: Survival time estimates in months for progression-free survival, overall survival and loco-regional control.
Survivala All patients
n = 78
Only radiotherapy
n = 48
Post-operative radiotherapy
n = 30
Progression-free 28.1 (23.8-32.4) 23.8 (18.2-29.4) 31.5 (26.0-36.9)
Overall 34.7 (30.6-38.9) 29.1 (23.9-34.3) 42.8 (38.4-47.2)
Loco-regional control 32.8 (28.6-37.1) 29.2 (23.4-35.0) 34.5 (29.7-39.4)
The survival time is calculated in all patients, only radiotherapy patients and post-operative radiotherapy patients.
aMean (95% confidence interval)BMC Cancer 2009, 9:458 http://www.biomedcentral.com/1471-2407/9/458
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Kaplan-Meier plot showing progression-free survival in patients Figure 1
Kaplan-Meier plot showing progression-free survival in patients. A) Pre-radiotherapy plasma total carotenoids above 
median (high total carotenoids) versus plasma total carotenoids below median values (low total carotenoids), log rank p = 
0.003; B) Relative decrease in plasma FRAP above median (high decrease in FRAP) versus relative decrease in plasma FRAP 
below median (low decrease in FRAP), log rank p = 0.024 and C) Relative increase in plasma d-ROMs above median (high 
increase in d-ROMs) versus relative increase in plasma d-ROMs below median (low increase in d-ROMs), log rank p = 0.006.
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Discussion
HNSCC patients have significantly lower levels of pre-
radiotherapy plasma dietary antioxidants, FRAP and mod-
ified FRAP as compared to healthy controls; and dietary
antioxidants further declined significantly during radio-
therapy. The oxidative stress biomarker, d-ROMs, was sig-
nificantly higher in patients as compared to controls and
increased significantly during radiotherapy. Furthermore,
pre-radiotherapy plasma carotenoids, relative increase in
plasma levels of d-ROMs and relative decrease in plasma
levels of FRAP during radiotherapy were positively associ-
ated with survival.
While low levels of pre-radiotherapy plasma β-carotene,
lycopene and vitamin E have been suggested in some pre-
liminary studies involving HNSCC patients [15-17], the
Table 5: Cox regression analysis showing association between survival and pre-radiotherapy plasma carotenoid levels.
Carotenoids Crude Adjusteda
Hazard rate ratio 95% CI p-value Hazard rate ratio 95% CI p-value
Progression-free survival
Lutein 0.40 0.20-0.80 0.01 0.47 0.22-0.98 0.04
zeaxanthin 0.49 0.25-0.97 0.04 0.55 0.27-1.09 0.09
β-cryptoxanthin 0.41 0.20-0.83 0.01 0.46 0.23-0.94 0.03
α-carotene 0.52 0.26-1.04 0.06 0.57 0.28-1.17 0.12
β-carotene 0.41 0.21-0.83 0.01 0.45 0.22-0.92 0.03
Lycopene 0.66 0.34-1.30 0.23 0.71 0.35-1.41 0.32
Total carotenoids 0.36 0.17-0.73 0.005 0.42 0.20-0.91 0.03
Overall survival
Lutein 0.30 0.12-0.72 0.007 0.39 0.16-0.96 0.04
zeaxanthin 0.40 0.17-0.93 0.03 0.49 0.21-1.14 0.10
β-cryptoxanthin 0.25 0.10-0.63 0.003 0.27 0.11-0.69 0.006
α-carotene 0.32 0.14-0.78 0.01 0.36 0.15-0.86 0.02
β-carotene 0.20 0.07-0.52 0.001 0.23 0.08-0.62 0.004
Lycopene 0.63 0.28-1.40 0.26 0.63 0.27-1.45 0.28
Total carotenoids 0.26 0.10-0.65 0.004 0.38 0.15-0.98 0.05
The above median levels- are compared with below median levels- of plasma carotenoids in 78 patients for progression-free and overall survivals.
aThe analysis are adjusted for stage, treatment and smoking status
Table 6: Cox regression analysis showing association between survival and relative changes in biomarkers.
Variables Crude Adjusted
Hazard rate ratio 95% CI p-value Hazard rate ratio 95% CI p-value
Progression-free survival
d-ROMs increase 0.33 0.14-0.76 0.01 0.31 0.13-0.76 0.01a
8-iso PGF2α
increase
0.48 0.22-1.08 0.08 0.51 0.22-1.17 0.11b
FRAP decrease 0.43 0.19-0.98 0.05 0.42 0.17-0.998 0.05c
Overall survival
d-ROMs increase 0.26 0.08-0.80 0.02 0.31 0.10-1.00 0.05a
8-iso PGF2α
increase
0.54 0.21-1.42 0.21 0.58 0.21-1.59 0.29b
FRAP decrease 0.39 0.14-1.10 0.07 0.52 0.18-1.56 0.25c
The above median relative changes in plasma levels of oxidative stress biomarkers (d-ROMs and 8-iso PGF2α) and total antioxidant capacity FRAP 
are compared with below median relative changes in the plasma levels of the corresponding biomarkers in 57 patients for progression-free and 
overall survivals.
aThe analysis are adjusted for stage, smoking status and tumour localization
bThe analysis are adjusted for stage, smoking status and age
cThe analysis are adjusted for stage, tumour localization and BMIBMC Cancer 2009, 9:458 http://www.biomedcentral.com/1471-2407/9/458
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present study is the first study where an extensive profile
of antioxidants are measured in HNSCC patients and
compared to healthy controls. The observed lower levels
of plasma carotenoids in HNSCC patients are in accord-
ance with the observation that low intake of carotenoid-
rich fruits and vegetables increase the risk of cancers in the
mouth, pharynx and larynx [10].
We also observed that these patients have high oxidative
stress prior to radiotherapy as reflected by significantly
higher plasma levels of d-ROMs as compared to healthy
controls. To our knowledge, this is the first observation
suggesting increased oxidative stress in newly diagnosed
HNSCC patients before treatment.
All the dietary antioxidants measured decreased after radi-
otherapy. The decrease in plasma dietary antioxidants
during radiotherapy is possibly a combination of reduced
intake of antioxidant-rich foods (i.e., due to eating prob-
lems caused by adverse effects of radiotherapy, or
decreased intake of fruits and vegetables) and increased
utilization of antioxidants by free radicals produced from
ionising radiations. Bäckström et al. [29] has shown that
HNSCC patients experiencing dry mouth symptoms dur-
ing radiotherapy have lower dietary intakes of β-carotene
and vitamin E. In our cohort of patients there was a signif-
icant weight loss during the treatment period (median
weight loss = 3.7%, p < 0.001). However, no significant
correlation between weight loss and reduction in plasma
antioxidant levels were observed (data not shown) sug-
gesting that dietary intake in general does not account for
this decline in plasma antioxidant levels. Thus, a specific
decreased intake of antioxidant-rich foods and increased
utilization of antioxidants during radiotherapy may be
the plausible explanations for this decline. Increased utili-
zation is in accordance with the observed increase in oxi-
dative stress biomarkers, d-ROMs, 8-iso-PGF2α and GGT
during radiotherapy.
We have investigated the role of a number of plasma anti-
oxidants and oxidative stress biomarkers on survival in
HNSCC patients. Our results demonstrated that among
different dietary antioxidant biomarkers, pre-radiother-
apy plasma lutein, β-cryptoxanthin, β-carotene and total
carotenoids are strong prognostic factors for progression-
free and overall survivals. The risk of progression was 60%
less in patients having plasma carotenoids above median
levels as compared to patients with under median levels.
After correcting for various confounding factors (stage,
treatment and smoking status), the relative risk remained
close to 50%. Meyer et el. [30] also shows that high levels
of plasma pre-radiotherapy β-carotene reduces rates of
local tumour recurrence in head and neck cancer patients.
This specific association of carotenoids with survival
among dietary antioxidants may be due to difference in
their chemical structure, compartmentalization and func-
tion as compared to other dietary antioxidants. Caroten-
oids are quenchers of singlet oxygen and are involved in
restoring gap junctional communication (GJC) [31]. GJC
is lost during carcinogenesis and may be important for
malignant transformation. Carotenoids have shown to
stimulate GJC in a differential and dose dependent man-
ner although the underlying mechanisms are not fully
understood [31].
We have previously shown that high levels of post-radio-
therapy plasma carotenoids (lutein, α-carotene and β-car-
otene) were positively associated with survival in HNSCC
patients [21]. Thus, plasma levels of several carotenoids,
measured both before and after radiotherapy, are posi-
tively associated with survival in HNSCC patients.
Relative changes in plasma levels of d-ROMs and FRAP
during radiotherapy showed an association with survival.
The risk of progression developing distant relapse, local
recurrence, regrowth or death was decreased by 70% and
60% for patients with an above median increase in d-
ROMs and above median decrease in FRAP respectively,
during treatment period. Relative changes in plasma levels
of oxidative stress biomarker for lipid peroxidation, 8-iso
PGF2α shows similar trend with survival after adjusting for
confounding factors (p = 0.11). The risk of progression
was decreased by 50% for patients with an above median
increase in plasma levels of 8-iso PGF2α. Both d-ROMs
and 8-iso PGF2α are biomarkers for oxidative stress, but
measure total and specific oxidative damage in the cells,
respectively. d-ROMs measure systemic oxidative damage
caused by ROS to a number of organic substrates in a cell
(e.g. lipids, amino acids, proteins, nucleotides and carbo-
hydrates), but 8-iso PGF 2α measures a more specific oxi-
dative damage mainly to polyunsaturated fatty acids in
the cells. The therapeutic effect of radiotherapy mainly
comes from production of ROS in tumour cells. Our
results, thus, indicate that patients with an increase in sys-
temic oxidative stress during radiotherapy had better pro-
gression-free survival suggesting that increased oxidative
stress may be beneficial during treatment period. We also
observed that the risk of progression and overall death,
respectively, were 80% and 87% less for the patients with
high level of total carotenoids and high increase in d-
ROMs as compared to low levels of both these factors
(above median levels compared to below median levels).
The strong combined adverse effect of low total caroten-
oid level and low increase in d-ROMs may identify a high-
risk group of patients that could be candidates for an
intervention trial.
Our data shows that high pre-radiotherapy plasma total
carotenoid status is beneficial for HNSCC patients.
Plasma total carotenoids are biomarkers of fruits and veg-BMC Cancer 2009, 9:458 http://www.biomedcentral.com/1471-2407/9/458
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etable intake. Plasma carotenoids may also reflect intake
of carotenoid supplement. However, β-carotene supple-
ments which increase plasma β-carotene significantly,
show no beneficial effects on mortality and development
of second primary tumours in head and neck cancer
patients [32,33], and even increase the risk of developing
lung cancer [10]. Thus, increased intake of carotenoids
through fruits and vegetables and not supplements in the
period before radiotherapy may be beneficial for HNSCC
patients.
Administration of carotenoid-rich fruits and vegetables
may be more problematic during radiotherapy since oxi-
dative stress mediates the therapeutic effects of radiother-
apy and we observed that increased oxidative stress was
beneficial during radiotherapy. To our knowledge, no
study to date has studied the effect of increased caroten-
oid-rich fruits and vegetables during radiotherapy on the
survival in this group of patients. Data from intervention
studies with supplements (both α-tocopherol and β-caro-
tene) in head and neck cancer patients during and after
radiotherapy showed the supplement group had less
severe side-effects of radiotherapy, but showed trends for
increased rates of recurrence [34] that were significant in
smokers [35]. Reasons for increased rates of recurrence
could be that the use of supplements and smoking reduce
radiation treatment efficacy.
Conclusion
Our data shows that plasma levels of pre-radiotherapy car-
otenoids in HNSCC patients are lower than healthy con-
trols, decrease during radiotherapy and are positively
associated with progression-free and overall survivals.
High oxidative stress during treatment period is also ben-
eficial for survival. The possible association between
intake of carotenoid-rich fruits and vegetables and sur-
vival of HNSCC patients before, during and after radio-
therapy should be investigated in future studies.
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